Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.51 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081974 | 0.93 | PLA2G4A (0.50) | CYSLTR2CYSLTR1CCR2PLA2G4AALOX5AP | |
| SCHEMBL3102127 | 0.80 | SRD5A2 (0.67) | PLA2G4ASRD5A2 | |
| SCHEMBL3559347 | 0.77 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1 | |
| SCHEMBL3559344 | 0.77 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1 | |
| SCHEMBL9756965 | 0.74 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL4322740 | 0.74 | PLA2G4A (0.57) | CCR2PLA2G4ASRD5A2 | |
| SCHEMBL3099629 | 0.73 | PLA2G4A (0.62) | PLA2G4ASRD5A2 | |
| SCHEMBL8650159 | 0.72 | CYSLTR1 (0.74) | CYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL8325040 | 0.71 | CYSLTR1 (0.74) | CYSLTR2CYSLTR1 | |
| SCHEMBL27393484 | 0.70 | CYSLTR1 (0.57) | CYSLTR2CYSLTR1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2481732-A1 | Condensed ring compound and use thereof | Ono Pharmaceutical Co., Ltd. (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | TAKEUCHI JUN | 2010-09-16 | — | — | US | disclosed |
| US-7763610-B2 | Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885CCR2 38/4885 |
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885CCR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.